BACKGROUND: MUC1 is associated with tumor invasion and metastasis, and is expressed in pancreatic cancer with a high frequency. This study explored whether MUC1 expression affected the survival of patients with pancreatic cancer. METHODS: Tissue specimens obtained from 70 patients with invasive ductal carcinoma of the pancreas, in pTNM stage III or IV, were immunostained with the anti-MUC1 monoclonal antibody DF3. The results of immunostaining were determined to be positive when more than 50% of the total cancer cells were positively stained. Association of the expression of the DF3 epitope with clinicopathological parameters or patients' survival was statistically evaluated. RESULTS: The incidence of positivity of MUC1 expression was 55.7% (39/70) and this incidence was significantly higher in pTNM stage IV than in stage III (odds ratio [OR], 4.015; 95% confidence interval [CI], 1.459-11.0541; P = 0.0076). As there was a clear difference in overall survival between pTNM stages III and IV ( P = 0.0016), the effect of MUC1 expression on survival was separately evaluated in each stage. It was shown that the expression of MUC1 was associated with unfavorable overall survival in stage IV ( P = 0.0197). CONCLUSIONS: Our data suggest that the expression of MUC1 may be related to the progression of pancreatic cancer.
BACKGROUND:MUC1 is associated with tumor invasion and metastasis, and is expressed in pancreatic cancer with a high frequency. This study explored whether MUC1 expression affected the survival of patients with pancreatic cancer. METHODS: Tissue specimens obtained from 70 patients with invasive ductal carcinoma of the pancreas, in pTNM stage III or IV, were immunostained with the anti-MUC1 monoclonal antibody DF3. The results of immunostaining were determined to be positive when more than 50% of the total cancer cells were positively stained. Association of the expression of the DF3 epitope with clinicopathological parameters or patients' survival was statistically evaluated. RESULTS: The incidence of positivity of MUC1 expression was 55.7% (39/70) and this incidence was significantly higher in pTNM stage IV than in stage III (odds ratio [OR], 4.015; 95% confidence interval [CI], 1.459-11.0541; P = 0.0076). As there was a clear difference in overall survival between pTNM stages III and IV ( P = 0.0016), the effect of MUC1 expression on survival was separately evaluated in each stage. It was shown that the expression of MUC1 was associated with unfavorable overall survival in stage IV ( P = 0.0197). CONCLUSIONS: Our data suggest that the expression of MUC1 may be related to the progression of pancreatic cancer.
Authors: Pankaj K Singh; Michelle E Behrens; John P Eggers; Ronald L Cerny; Jennifer M Bailey; Kandavel Shanmugam; Sandra J Gendler; Eric P Bennett; Michael A Hollingsworth Journal: J Biol Chem Date: 2008-07-14 Impact factor: 5.157
Authors: Elaine Cristina Morari; Joyce Rosário Silva; Ana Carolina Trindade Guilhen; Lucas Leite Cunha; Marjory Alana Marcello; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward Journal: Endocr Pathol Date: 2010-12 Impact factor: 3.943
Authors: M Saitou; M Goto; M Horinouchi; S Tamada; K Nagata; T Hamada; M Osako; S Takao; S K Batra; T Aikou; K Imai; S Yonezawa Journal: J Clin Pathol Date: 2005-08 Impact factor: 3.411